JP2016519128A5

JP2016519128A5 -

Download PDF

Info

Publication number: JP2016519128A5
Authority: JP; Japan
Prior art keywords: composition; composition according; snac; peptide; ethoxy
Prior art date: 2014-05-02
Legal status : Granted

Application number

JP2016511088A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016519128A (ja

JP6672140B2 (ja

Filing date

2014-05-02

Publication date

2017-06-15

2014-05-02 Application filed filed Critical

2014-05-02 Priority claimed from PCT/EP2014/058974 external-priority patent/WO2014177683A1/en

2016-06-30 Publication of JP2016519128A publication Critical patent/JP2016519128A/ja

2017-06-15 Publication of JP2016519128A5 publication Critical patent/JP2016519128A5/ja

2019-12-25 Priority to JP2019235054A priority Critical patent/JP7576910B2/ja

2020-03-25 Application granted granted Critical

2020-03-25 Publication of JP6672140B2 publication Critical patent/JP6672140B2/ja

Status Active legal-status Critical Current

2034-05-02 Anticipated expiration legal-status Critical

Links

239000000203 mixture Substances 0.000 claims 40
UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 11
108090000765 processed proteins & peptides Proteins 0.000 claims 9
DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical group CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 5
229950011186 semaglutide Drugs 0.000 claims 5
108010060325 semaglutide Proteins 0.000 claims 5
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 3
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 3
239000003623 enhancer Substances 0.000 claims 3
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
230000002265 prevention Effects 0.000 claims 3
150000003839 salts Chemical group 0.000 claims 3
-1 4-carboxyphenoxy Chemical group 0.000 claims 2
208000008589 Obesity Diseases 0.000 claims 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
235000020824 obesity Nutrition 0.000 claims 2
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 1
229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
235000019359 magnesium stearate Nutrition 0.000 claims 1
229940057948 magnesium stearate Drugs 0.000 claims 1
235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
239000008108 microcrystalline cellulose Substances 0.000 claims 1
229940016286 microcrystalline cellulose Drugs 0.000 claims 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
229940069328 povidone Drugs 0.000 claims 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
239000008247 solid mixture Substances 0.000 claims 1
208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1

JP2016511088A 2013-05-02 2014-05-02 Ｇｌｐ−１化合物の経口投薬 Active JP6672140B2 (ja)